Levi & Korsinsky, LLP announces that a ARDX class action lawsuit has been filed on behalf of investors who purchased Ardelyx Inc. (ARDX) securities between August 6, 2020 and July 19, 2021. For more on the ARDX Lawsuit please contact us today.
According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: the likelihood that tenapanor would be approved by the Food and Drug Administration (“FDA”). Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug’s treatment effect, making it foreseeably likely that the FDA would not approve the drug.
If you suffered a loss in you have until September 28, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.